Pharma & Life Sciences
Genome Engineering: CRISPR Frontiers
The 7th Genome Editing Therapeutics Summit is a three-day event focused on advancing genome editing therapies, including in vivo and ex vivo gene editing. It is designed for R&D, preclinical, translational, regulatory, and executive leaders in biopharma and related fields to discuss scientific innovation, safety, clinical efficacy, and regulatory compliance.
The essentials
Event details
- Dates
- August 2026
- Location
- Hilton Boston Logan Airport, United States
- Organiser
- 7th Genome Editing Therapeutics Summit 2026
- Expected attendance
- 23
- Industry
- Pharma & Life Sciences
Agenda themes
Topics covered
- Science & Research
- Education & Training
On stage
Speakers
- Ishani Dasgupta, Senior Scientist, AbbVie
- Devyn Smith, Chief Executive Officer, Arbor Biotechnologies
- Gopi Shanker, Chief Scientific Officer, Beam Therapeutics
- Matthew Laurie, Senior Scientist, Bristol Myers Squibb
- Wenning Qin, Senior Vice President - Research, eGenesis Bio
- John Moore, Senior Director - Translational Gene Editing, Eli Lilly
- Birgit Schultes, Chief Scientific Officer, Intellia Therapeutics
- Alan Brooks, Senior Vice President, Research, Metagenomi Therapeutics
- Cindy Liu, Director - Molecular Analytical Development, Prime Medicine
On the floor
Sponsors and partners
- Aldevron
- Broken String Biosciences
- Cirena
- MaxCyte
- Lonza
- Sumitomo Chemical Advanced Medical Solutions America LLC (SC-AMSA)
Keep planning
Related events
Spot something wrong on this page? Report a correction and we will fix it.